213 related articles for article (PubMed ID: 14513369)
1. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Verschraegen CF; Kumagai S; Davidson R; Feig B; Mansfield P; Lee SJ; Maclean DS; Hu W; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Oct; 129(10):549-55. PubMed ID: 14513369
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Perez-Soler R; Lopez-Berestein G; Lautersztain J; al-Baker S; Francis K; Macias-Kiger D; Raber MN; Khokhar AR
Cancer Res; 1990 Jul; 50(14):4254-9. PubMed ID: 2364384
[TBL] [Abstract][Full Text] [Related]
5. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery.
Khokhar AR; Wright K; Siddik ZH; Perez-Soler R
Cancer Chemother Pharmacol; 1988; 22(3):223-7. PubMed ID: 3409456
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
7. Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles.
Perez-Soler R; Yang LY; Drewinko B; Lauterzstain J; Khokhar AR
Cancer Res; 1988 Aug; 48(16):4509-12. PubMed ID: 3396003
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes.
Khokhar AR; al-Baker S; Krakoff IH; Perez-Soler R
Cancer Chemother Pharmacol; 1989; 23(4):219-24. PubMed ID: 2647311
[TBL] [Abstract][Full Text] [Related]
9. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
Perez-Soler R; Khokhar AR; Lopez-Berestein G
Cancer Res; 1987 Dec; 47(24 Pt 1):6462-6. PubMed ID: 3315188
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L
Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes.
Lautersztain J; Perez-Soler R; Turpin J; Khokhar AR; Siddik ZH; Schmidt K; Lopez-Berestein G
Cancer Res; 1988 Mar; 48(5):1300-6. PubMed ID: 3342409
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats.
Fox LE; Toshach K; Calderwood-Mays M; Khokhar AR; Kubilis P; Perez-Soler R; MacEwen EG
Am J Vet Res; 1999 Feb; 60(2):257-63. PubMed ID: 10048562
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
[TBL] [Abstract][Full Text] [Related]
15. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
Perez-Soler R; Khokhar AR
Cancer Res; 1992 Nov; 52(22):6341-7. PubMed ID: 1423280
[TBL] [Abstract][Full Text] [Related]
16. Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent.
Maclean DS; Khokhar AR; Tyle P; Perez-Soler R
J Microencapsul; 2000; 17(3):307-22. PubMed ID: 10819419
[TBL] [Abstract][Full Text] [Related]
17. Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Perez-Soler R; Lautersztain J; Stephens LC; Wright K; Khokhar AR
Cancer Chemother Pharmacol; 1989; 24(1):1-8. PubMed ID: 2720887
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
20. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
